Alpha Clinics Trials

The Alpha Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. 

Browse the list of ongoing trials at Alpha Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha ClinicAlpha Clinic ContactTrial SponsorDisease IndicationClinical Trial NameStatus of EnrollmentLearn More
UC Davis & UCSD & UCI & UCSF & City of Hope
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Pact Pharma & CIRM Solid tumors A Phase 1a/1b, Open Label First In Human Study Of The Safety, Tolerability And Feasibility Of Gene Edited Autologous NeoTCR T Cells (NeoTCR-P1) Administered As A Single Agent Or In Combination With Anti PD-1 To Patients With Locally Advanced Or Metastatic No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis/CIRM Spina bifida Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele Recruiting
UC Davis Orca Biosystems, Inc. Hematologic Malignancies A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood, With Single Agent Graft Versus-host Disease Prophylaxis, in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Atara Bio. EBV-PTLD Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Kite Pharma Advanced Cancer A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Pluristem Ltd. Muscle Injury - hip fracture Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty Recruiting
UC Davis
Jane McCluskepy
916-703-9302
jmccluskey@ucdavis.edu
Medeor Therapuetics Kidney Transplant Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis B-Cell Leukemia A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies Active, not recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis Cancer - Lymphoma (HIV-Related) Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Nohla Therapeutics Cancer – Leukemia Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Capricor Therapeutics Muscle - Duchenne Muscular Dystrophy A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2) No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis Cancer - Tongue Dysphagia Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis Eye - Retinopathy Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy Recruiting
UCI
Julia Kimberly Fong
juliakf@hs.uci.edu
Cartesian Therapeutics MYASTHENIA GRAVIS (MG) Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) Recruiting
UCI & UC Davis
UCI: Jennifer Scott
714-456-4956
scottj2@uci.edu

UC Davis: Kate Trigg
916-734-8033
ktrigg@ucdavis.edu
Celularity, Inc. Hospitalized COVID-19 patients A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 Active, not recruiting
UCI
Jennifer Scott
714-456-5956
scottj2@uci.edu
Pluristem Ltd. Intubated COVID-19 patients A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19 No longer active
UCI
Breana Chew
949-824-8116
chewbc@hs.uci.edu
Brain Neurotherapy Bio Parkinson's Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson’s Disease Active, not recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
ReNeuron Limited Stroke A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects with Disability Following an Ischemic Stroke (PISCES III) No longer active
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
Pluristem Ltd. Critical Limb Ischemia (CLI) A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Subjects with Critical Limb Ischemia (CLI) with Minor No longer active
UCI & UC Davis
UCI Stem Cell Clinic: Roy Fujitani
949-824-3990
stemcell@uci.edu
Humacyte Kidney failure A Phase 3 Study to Compare the Efficacy and Safety of Humacyte’s Human Acellular Vessel With That of an Autologous Arteriovenous Fistula in Subjects With End Stage Renal Disease Active, not recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
Stratetech Burn wounds StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements No longer active
UCI & UCSD & UC Davis
UCI Stem Cell Clinic
949-824-3990
stemcell@uci.edu

Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Aivita Biomedical Cancer - Brain Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma Active, not recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
Longeveron Aging frailty Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty Active, not recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
BrainStorm Cell Therapeutics Amyotrophic Lateral Sclerosis (ALS) A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and safety of repeated administrations of NurOwn® (autologous mesenchymal stem cells secreting neurotrophic factors) in participants with ALS No longer active
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
jCyte Eye - Retinitis Pigmentosa (RP) Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa No longer active
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu

SanBio Stroke Study of Modified Stem Cells in Patients With Chronic Motor Deficit From Ischemic Stroke No longer active
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
ImmunoCellular Therapeutics Cancer - Brain A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma No longer active
UCI & UC Davis
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu

UC Davis: Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Humacyte Kidney Failure An Assessment of Humacyte’s Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) No longer active
UCLA
Scott Nowicki, MD, PhD

Ignacio Baselga Carretero, PhD
310-206-2090
IBaselga@mednet.ucla.edu
UCLA Cancer - Solid Tumors Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies No longer active
UCLA
Lia Etheridge
(310-825-7174)
letheridge@mednet.ucla.edu
UCLA Cancer - Lung A Phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC Active, not recruiting
UCLA
Sarah Larson, MD
310-206-8477
slarson@mednet.ucla.edu
UCLA Cancer TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM) No longer active
UCLA
Maricela Gonzalez
(310) 557-3729
mmgonzalez@mednet.ucla.edu
Calimmune HIV/AIDS Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection No longer active
UCLA
Caroline Kuo, MD
310-794-1940
ckuo@mednet.ucla.edu
UCLA X-linked Chronic Granulomatous Disease Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease Active, not recruiting
UCLA
Fabrizia Urbinati, PhD
(310) 794-1884
furbinati@ucla.edu
UCLA Sickle Cell Disease Stem Cell Gene Therapy for Sickle Cell Disease Recruiting
UCLA
Kit L Shaw, PhD
(310) 267-0584
kshaw@mednet.ucla.edu
UCLA Severe Combined Immunodeficiency (SCID) Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) Active, not recruiting
UCLA
Kit L Shaw, PhD
(310) 267-0584
kshaw@mednet.ucla.edu
Orchard Therapeutics Severe Combined Immunodeficiency (SCID) Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency Active, not recruiting
UCLA & UCI
UCLA: Courtney Real, BSN
310-267-7433
creal@mednet.ucla.edu

UCI: UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
SanBio Brain Injury A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI) No longer active
UCSD UCSD & CIRM Cystinosis Stem cell gene therapy for cystinosis Recruiting
UCSD Tigenix Crohn's Disease Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn’s Disease (CD) Active, not recruiting
UCSD Calibr Relapsed/Refractory B-cell Lymphomas Long term follow-up study for patients administered CLBR001 , a CAR-T cell No longer active
UCSD Calibr Relapsed/Refractory B-cell Lymphomas CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies No longer active
UCSD Fate Therapeutics Solid tumors FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors No longer active
UCSD
Benjamin M Heyman, MD
858-246-3038
bheyman@ucsd.edu
UCSD/Oncternal chronic lymphocytic leukemia Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax Active, not recruiting
UCSD Aivita Ovarian and Fallopian Tube Carcinoma Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas Active, not recruiting
UCSD
Teresa Rzesiewicz
844-317-7836
alphstemcellclinic@ucsd.edu
Discgenics Degenerative Disc Disease Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration No longer active
UCSD
Barbara Parker, MD
858-822-6135
baparker@ucsd.edu

Rebecca Shatsky, MD
858-657-7000
rshatsky@ucsd.edu
UCSD Cancer - Breast Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer Active, not recruiting
UCSD Persimmune, Inc. Cancer - Blood Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) No longer active
UCSD & City of Hope UCSD Cancer - Leukemia A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Active, not recruiting
UCSD
UCSD Stem Cell Clinic
(844) 317-7836
alphastemcellclinic@ucsd.edu
Persimmune, Inc. Cancer - Blood Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens No longer active
UCSD Asterias Biotherapeutics Spinal Cord Injury Dose Escalation Study of AST-OPC1 in Spinal Cord Injury No longer active

Clinical trials conducted at CIRM Alpha Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials. If you or a family member is interested in participating in a clinical trial, please visit clinicaltrials.gov to find a trial near you.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News